Indian government plans to foster SMEs and bulk drug industry

27 June 2018

Aiming to reduce the cost of bulk drugs by 20%-25% and to help small and medium pharmaceutical enterprises (SMEs) upgrade their technology, the Indian government is looking to pump in several millions to support and shore up the drug industry, reports The Pharma Letter’s India correspondent.

The government is keen to provide assistance to the bulk drug industry to "ease the competitiveness, provide easy access to standard testing and infrastructure facilities and value addition" through the creation of common facility centers. Proposed as a central sector scheme, the total size of the bulk drug scheme has been placed at $29 million for 2018-2020.

"The aim is to strengthen the existing infrastructure facilities in order to make the Indian bulk drug industry a global leader in bulk drug exports," said an official. Reducing the cost of production in the bulk drug park will also lead to better availability and affordability of bulk drugs in the domestic market, the official added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK